Translocation of lysophosphatidic acid phosphatase in response to gonadotropin-releasing hormone to the plasma membrane in ovarian cancer cell

被引:7
作者
Sun, WS
Imai, A [1 ]
Sugiyama, M
Furui, T
Tamaya, T
Saio, M
Morris, AI
机构
[1] Gifu Univ, Sch Med, Dept Obstet & Gynecol, Gifu 5008705, Japan
[2] Gifu Univ, Sch Med, Dept Pathol 2, Gifu 5008705, Japan
[3] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA
关键词
phosphatase; lysophosphatidic acid; ovarian cancer; gonadotropin-releasing hormone; antiproliferative action;
D O I
10.1016/j.ajog.2004.01.038
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Lysophosphatidic acid mediates proliferative and/or morphologic effects on multiple cell lineages, which include ovarian cancer cells. Lysophosphatidic acid hydrolysis limits the duration of lysophosphatidic acid's action. We examined hormonal translocation of lipid phosphate phosphatase type 3 to the plasma membrane in gonadotropin-releasing hormone-responsive ovarian cancers. Study design: Ovarian cancers that were removed surgically and the ovarian cancer cell lines Caov-3 and SK-OV-3 were examined. Lipid phosphate phosphatase type 3 protein and activity in plasma membranes were assessed by immunohistochemical staining with lipid phosphate phosphatase type 3-specific antibodies and by the measurement of the conversion of exogenous [H-3-oleoyl]lysophosphatidic acid to mono [H-3-oleoyl] glycerol, respectively. Results: In ovarian cancers that were removed surgically, the cell surface staining and activity measurements indicated that a portion of the enzyme was localized to the plasma membrane. In Caov-3 cells and SK-OV-3 cells, lipid phosphate phosphatase type 3 protein was present both in the cytoplasm and at the plasma membrane. Treatment of the cells with a gonadotropin-releasing hormone agonist buserelin produced a rapid and progressive translocation of lipid phosphate phosphatase type 3 protein to the plasma membrane, with a concomitant loss of cytoplasmic staining. The enzyme activity in plasma membrane was also increased when the cell lines were exposed to the gonadotropin- releasing hormone agonist in intact cells before the assay of the cell membranes. Conclusion: These findings support the presence of lipid phosphate phosphatase type 3 in plasma membrane of ovarian cancers and provide for the ability of agonists (such as gonadotropin-releasing hormone) to induce the translocation of lipid phosphate phosphatase type 3 to plasma membrane in ovarian cancer cells. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 31 条
[1]   The Dri 42 gene, whose expression is up-regulated during epithelial differentiation, encodes a novel endoplasmic reticulum resident transmembrane protein [J].
Barila, D ;
Plateroti, M ;
Nobili, F ;
Muda, AO ;
Xie, YH ;
Morimoto, T ;
Perozzi, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (47) :29928-29936
[2]   Mammalian lipid phosphate phosphohydrolases [J].
Brindley, DN ;
Waggoner, DW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (38) :24281-24284
[3]   Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells [J].
Emons, G ;
Ortmann, O ;
Schulz, KD ;
Schally, AV .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1997, 8 (09) :355-362
[4]  
Frankel A, 1996, CLIN CANCER RES, V2, P1307
[5]   Lysophospholipid receptors [J].
Fukushima, N ;
Ishii, I ;
Contos, JJA ;
Weiner, JA ;
Chun, J .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :507-534
[6]   Lysophospholipids - Receptor revelations [J].
Hla, T ;
Lee, MJ ;
Ancellin, N ;
Paik, JH ;
Kluk, MJ .
SCIENCE, 2001, 294 (5548) :1875-1878
[7]   THE USE OF ANTIAVIDIN ANTIBODY AND AVIDIN - BIOTIN - PEROXIDASE COMPLEX IN IMMUNOPEROXIDASE TECHNIQUES [J].
HSU, SM ;
RAINE, L ;
FANGER, H .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1981, 75 (06) :816-821
[8]  
IMAI A, 1987, METHOD ENZYMOL, V141, P100
[9]  
Imai A, 2000, Vitam Horm, V59, P1, DOI 10.1016/S0083-6729(00)59002-5
[10]   A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within time plasma membrane of ovarian cancer cells [J].
Imai, A ;
Furui, T ;
Tamaya, T ;
Mills, GB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (09) :3370-3375